Community engagement is often cited as a tool to improve the health of the community and its members. This guide will review evidence related to leveraging community engagement to support the implementation and scale-up of evidence-based programs and policies.

This 18x24 inch poster helps publicize the new 988 Suicide & Crisis Lifeline and provides access to this life-saving resource. This poster is designed to be placed in community centers, counseling offices, clinics, and other settings where people gather.

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

This updated manual contains a 12-week cognitive–behavioral anger management group treatment model. The content includes specific instructions and suggested remarks for group leaders, and exercises for group members. This model will work in a variety of clinical settings, and with diverse audiences.

This updated manual contains a 12-week cognitive–behavioral anger management group treatment model. The content includes specific instructions and suggested remarks for group leaders, and exercises for group members. This model will work in a variety of clinical settings, and with diverse audiences.

This updated manual contains a 12-week cognitive–behavioral anger management group treatment model. The content includes specific instructions and suggested remarks for group leaders, and exercises for group members. This model will work in a variety of clinical settings, and with diverse audiences.

This poster is for clients and their family members in OUD treatment who are pregnant or who are currently not pregnant but of childbearing age.

This publication provides an overview of federal disclosure laws affecting private-sector, employer sponsored group health plans and health insurers. This document is not a comprehensive description of these laws and should not be considered legal advice.